ClinicalTrials.gg
CompletedNCT00687219Updated Apr 7, 2017Results posted

Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

A Phase 3 interventional study of Peginterferon alfa-2b and Ribavirin in Hepatitis C, Chronic and Liver Cirrhosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
102
Allocation
Not applicable
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
19th of 39
102 · median 99
Started
2007
with 3 others
Phase 3
22 of 40
none open now
Registered
21st of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 19th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2007, is one of 22 in phase 3, and was the 21st registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

The objective is to evaluate the efficacy and safety of combination therapy with peginterferon alfa-2b 1.0 µg/kg/week subcutaneous (SC) + ribavirin administered for 48 weeks in participants with chronic hepatitis C and type C compensated liver cirrhosis. Participants who are hepatitis C virus ribonucleic acid (HCV-RNA) positive after 24 weeks of treatment will be discontinued from therapy.

03

Conditions studied

  • Hepatitis C, Chronic
  • Liver Cirrhosis

Keywords

  • hepatitis C
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 20-70 years.
  • Positive quantitative serum .
  • Participants classified as A in classification, and who do not have ascites or hepatic encephalopathy.
  • Diagnosed with type C compensated liver cirrhosis based on liver performed within 3 years or latest celioscopy.
  • Prolonged by \<=3.0 sec.
  • Participants and partners of participants willing to use adequate during the course of the study.
  • Participants who can be hospitalized for at least 14 days since treatment initiation.
  • Weight >40 kg and \<=100 kg
  • Hematology laboratory results of:

    • >=12 g/dL
    • >=1,500/mm\^3
    • count >=70,000/ mm\^3
  • Blood chemistry results of:

    • albumin and direct within normal limits
    • alpha fetoprotein (AFP) within reference range
    • AFP-L3\<=10%
    • Protein induced by vitamin K (PIVKA)-II \<=100 mAU/mL

Exclusion criteria

Exclusion Criteria:

  • Participants who did not previously respond virologically to combination therapy with interferon (including polyethylene glycol-modified interferon) and ribavirin
  • Participants who had previously received treatment with interferon for whom at least 90 days have not elapsed since the end of previous treatment
  • Participants who have received treatment within 14 days prior to registration with injectable preparations containing glycyrrhizin/cysteine/glycyron or shosaikoto
  • Participants who have received administration of drugs having antiviral, anti-tumor, or immuno-modulating effect (including and radiation therapy) within 90 days prior to registration (excluding local administration and topicals)
  • Participants who have received other drugs within 180 days prior to registration
  • surface (HBs) antigen positive
  • Antinuclear antibody >=320 times
  • Serum creatinine exceeding the upper limit of reference range
  • Participants with fasting blood glucose >=110 mg/dL (participants with fasting blood glucose >=110 mg/dL and \<126 mg/dL can be registered if their (HbA1c) is \<6.5%) [fasting blood glucose should be measured when participants are not receiving treatment for diabetes mellitus]
  • Participants with any of the following: diabetes mellitus that requires treatment; thyroid function disorder not controlled by treatment; liver disease such as , alcoholic and drug-induced liver diseases; hemophilia; arrhythmia requiring treatment; co-existing hypertension not controlled by drug therapy (systolic blood pressure [BP] >=160mmHg or diastolic BP>=100mmHg); chronic pulmonary disease; hemoglobinopathies (thalassemia, sickle cell anemia); malignant tumors or who have a history of malignant tumor within the past 5 years; organ transplants (other than cornea and hair transplant)
  • Participants with or who have a history of primary biliary cirrhosis, liver failure, hepatic carcinoma; decompensated liver cirrhosis with any the following diseases: ascites, jaundice, variceal hemorrhage, esophageal or gastric varices requiring treatment, hepatic encephalopathy, and idiopathic bacterial peritonitis; depression or schizophrenia requiring treatment, or suicidal attempt or suicidal ideation; epileptic seizures requiring treatment; angina, cardiac failure, myocardial infarction, or life-threatening arrhythmia; autoimmune disease (Hashimoto's disease, Crohn's disease, ulcerative colitis, chronic rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); hepatic carcinoma
  • Participants with a history of to interferon preparations, biological products such as vaccine, or nucleoside analogs, and those with specific reaction to pegylated interferon alfa-2b in the prick test conducted before the initiation of treatment
  • Women who are pregnant or nursing as well as women for whom pregnancy cannot be ruled out by serum human chorionic gonadotropin (HCG) test conducted during the screening period. Male participants with partners who are pregnant.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Peginterferon alfa-2b + Ribavirin

    Biological: Peginterferon alfa-2b · Drug: Ribavirin

Interventions

  • Administered at 1.0 µg/kg/week SC for 48 weeks

    Also known as: SCH 054031

  • Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening \>=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening \>=12g/dL and \<14g/dL; treatment duration is 48 weeks

    Also known as: SCH 018908

06

What researchers measure

Primary outcomes

  1. Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)

    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

    Time frame: Measured at 24 weeks after 48 weeks treatment (72 weeks)

Secondary outcomes

  1. Number of Participants With Undetectable HCV-RNA at Week 24

    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

    Time frame: Week 24

  2. Number of Participants With Undetectable HCV-RNA at End of Treatment

    Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

    Time frame: Up to 48 weeks

07

Results

Posted Dec 2, 2011

Participant flow

Participant flow — Overall Study
MilestonePeginterferon Alfa-2b + Ribavirin
Started102
Completed51
Not completed51
Withdrew: Adverse event8
Withdrew: Discontinuance criteria met7
Withdrew: Hcv-rna positive conversion34
Withdrew: Withdrawal by subject1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryNumber of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)

Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

Time frame:
Measured at 24 weeks after 48 weeks treatment (72 weeks)
Reported as:
Number · Participants
Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)
ParticipantsPeginterferon Alfa-2b + Ribavirin
Undetectable HCV-RNA41
Detectable HCV-RNA40
Unknown (data not available)21
SecondaryNumber of Participants With Undetectable HCV-RNA at Week 24

Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants With Undetectable HCV-RNA at Week 24
ParticipantsPeginterferon Alfa-2b + Ribavirin
Undetectable HCV-RNA61
Detectable HCV-RNA35
Unknown (data not available)6
SecondaryNumber of Participants With Undetectable HCV-RNA at End of Treatment

Serum HCV-RNA was qualitatively measured by reverse transcriptase polymerase chain reaction (RT-PCR)

Time frame:
Up to 48 weeks
Reported as:
Number · Participants
Number of Participants With Undetectable HCV-RNA at End of Treatment
ParticipantsPeginterferon Alfa-2b + Ribavirin
Undetectable HCV-RNA59
Detectable HCV-RNA43
Unknown (data not available)0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Peginterferon Alfa-2b + Ribavirin—14/102 (13.7%)102/102 (100%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventPeginterferon Alfa-2b + Ribavirin
HEPATIC NEOPLASM MALIGNANTNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/102
CATARACTEye disorders2/102
ATRIAL FIBRILLATIONCardiac disorders1/102
DIPLOPIAEye disorders1/102
VARICES OESOPHAGEALGastrointestinal disorders1/102
MALAISEGeneral disorders1/102
BURSITIS INFECTIVEInfections and infestations1/102
PNEUMONIAInfections and infestations1/102
SKIN LACERATIONInjury, poisoning and procedural complications1/102
LYMPHOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/102
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPeginterferon Alfa-2b + Ribavirin
PYREXIAGeneral disorders96/102
WHITE BLOOD CELL COUNT DECREASEDInvestigations94/102
HAEMOGLOBIN DECREASEDInvestigations91/102
MALAISEGeneral disorders90/102
LYMPHOCYTE COUNT DECREASEDInvestigations89/102
NEUTROPHIL COUNT DECREASEDInvestigations87/102
RED BLOOD CELL COUNT DECREASEDInvestigations86/102
HEADACHENervous system disorders83/102
HAEMATOCRIT DECREASEDInvestigations82/102
PLATELET COUNT DECREASEDInvestigations65/102

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Peginterferon Alfa-2b + Ribavirin
Mean58.6 ± 8.1
Sex: Female, Male
Sex: Female, Male(Participants)Peginterferon Alfa-2b + Ribavirin
Female48
Male54
Region of Enrollment
Region of Enrollment(Participants)Peginterferon Alfa-2b + Ribavirin
Japan102
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Oct 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2008
First posted
May 30, 2008
Start
Jun 2007
Primary completionActual
Oct 2010
CompletionActual
Oct 2010
Results first posted
Dec 2, 2011
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00687219
Responsible party
Sponsor
First posted
May 30, 2008
Start date
Jun 2007
Primary completion
Oct 2010
Completion
Oct 2010
Results posted
Dec 2, 2011
Last update
Apr 7, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion